Drug Profile

Influenza A virus vaccine H5N1 - Adimmune Corporation

Alternative Names: AdimFlu-W; AdimFlu-W (H5N1); AdimFlu-W (H5N1) Pandemic Influenza Vaccine - Adimmune

Latest Information Update: 27 Dec 2019

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Adimmune Corporation
Class Influenza A virus H5N1 vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Influenza A virus H5N1 subtype

Most Recent Events

27 Dec 2019 Discontinued - Phase-I/II for Influenza A virus H5N1 subtype (Prevention) in Taiwan (IM) (Adimmune Corporation website, December 2019)
14 Dec 2015 Clinical development is ongoing in Taiwan
01 Jul 2012 Phase-I/II clinical trials in Influenza-A virus H5N1 subtype (prevention) in Taiwan (IM)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com